Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more

Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

85.47M

52 Wk Range

$2.14 - $24.15

Previous Close

$4.57

Open

$4.19

Volume

604,128

Day Range

$4.15 - $4.98

Enterprise Value

92.81M

Cash

88.43M

Avg Qtr Burn

-8.04M

Insider Ownership

16.18%

Institutional Own.

69.92%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date